Literature DB >> 8750176

Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viremia.

T Tanaka1, J Y Lau, M Mizokami, E Orito, E Tanaka, K Kiyosawa, K Yasui, Y Ohta, A Hasegawa, S Tanaka.   

Abstract

The viral load of hepatitis C virus, as reflected by hepatitis C virus viremia, has been shown to have important clinical implications. In this study the hepatitis C virus core protein level in serum was evaluated for the detection and quantification of hepatitis C virus viremia. Hepatitis C virus core protein in serum was detected using a simple and sensitive fluorescent enzyme immunoassay. Hepatitis C virus core protein was quantitated in 100 healthy subjects, 258 patients with hepatitis C virus infection and 108 patients with non-hepatitis-C-virus-related chronic liver diseases. HCV-RNA was determined using the branched DNA (bDNA) assay and reverse-transcription polymerase chain reaction. The detection limit of this fluorescent enzyme immunoassay was found between 10(4) - 10(5) copies/ml HCV-RNA equivalent. There was a good correlation between the core protein and bDNA assay results (p <0.01). Hepatitis C virus core protein was detected in 81% of patients with hepatitis C virus infection (acute hepatitis 4/5, chronic hepatitis 85/104, cirrhosis 64/73 and hepatocellular carcinoma 56/76) but in none of the healthy subjects and patients with non-hepatitis C virus chronic liver diseases. The amount of hepatitis C virus core protein in patients with hepatitis-C-virus-related hepatocellular carcinoma was lower compared to chronic hepatitis and cirrhosis (p <0.05). All 26 patients treated with interferon-alpha showed parallel changes between HCV-RNA and core protein levels. This fluorescent enzyme immunoassay is simple and quick (assay time <3 h) with sensitivity at least matching the bDNA assay. Similar levels of hepatitis C virus core protein were detected in patients with chronic hepatitis and cirrhosis, but patients with hepatocellular carcinoma tended to have a lower level of hepatitis C virus core protein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8750176     DOI: 10.1016/0168-8278(95)80043-3

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  23 in total

Review 1.  Medicinal plants against hepatitis C virus.

Authors:  Usman A Ashfaq; Sobia Idrees
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Quantification of serum hepatitis C virus core protein level in patients chronically infected with different hepatitis C virus genotypes.

Authors:  E Orito; M Mizokami; T Tanaka; J Y Lau; K Suzuki; M Yamauchi; Y Ohta; A Hasegawa; S Tanaka; M Kohara
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

3.  Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets.

Authors:  G Barba; F Harper; T Harada; M Kohara; S Goulinet; Y Matsuura; G Eder; Z Schaff; M J Chapman; T Miyamura; C Bréchot
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  Comparison of a newly developed automated and quantitative hepatitis C virus (HCV) core antigen test with the HCV RNA assay for clinical usefulness in confirming anti-HCV results.

Authors:  Recep Kesli; Hakki Polat; Yuksel Terzi; Muhammet Guzel Kurtoglu; Yavuz Uyar
Journal:  J Clin Microbiol       Date:  2011-09-21       Impact factor: 5.948

5.  Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load.

Authors:  Tatsuji Kimura; Akinori Rokuhara; Yoko Sakamoto; Shintaro Yagi; Eiji Tanaka; Kendo Kiyosawa; Noboru Maki
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

6.  Development of a TT virus DNA quantification system using real-time detection PCR.

Authors:  T Kato; M Mizokami; M Mukaide; E Orito; T Ohno; T Nakano; Y Tanaka; H Kato; F Sugauchi; R Ueda; N Hirashima; K Shimamatsu; M Kage; M Kojiro
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

7.  Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes.

Authors:  K Nishioji; T Okanoue; Y Itoh; S Narumi; M Sakamoto; H Nakamura; A Morita; K Kashima
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

8.  The native form and maturation process of hepatitis C virus core protein.

Authors:  K Yasui; T Wakita; K Tsukiyama-Kohara; S I Funahashi; M Ichikawa; T Kajita; D Moradpour; J R Wands; M Kohara
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia.

Authors:  D Sansonno; G Lauletta; L Nisi; P Gatti; F Pesola; N Pansini; F Dammacco
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

10.  Stable replication of the EBNA1/OriP-mediated baculovirus vector and its application to anti-HCV gene therapy.

Authors:  Hitoshi Suzuki; Norihiko Matsumoto; Tomoyuki Suzuki; Myint Oo Chang; Hiroshi Takaku
Journal:  Virol J       Date:  2009-10-02       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.